Benzodiazepine Dependence Clinical Trial
Official title:
Gabapentin Treatment of Benzodiazepine Dependence
Benzodiazepine dependence is a growing public health problem for which very few evidenced-based treatment approaches are available. Approximately 683,000 individuals met past year criteria for sedative-hypnotic use disorders in the US during 2010, a prevalence greater than heroin or methamphetamine dependence. The most commonly prescribed sedative-hypnotic agents are the benzodiazepines. Chronic use induces pharmacodynamic tolerance in the GABA neurotransmitter system and individuals with physiological dependence find benzodiazepines difficult to discontinue because of withdrawal or rebound symptoms, which include autonomic arousal, depression, anxiety, and insomnia. Available evidence-based treatment approaches have been primarily directed at therapeutic users of benzodiazepines who do not meet criteria for a substance use disorder, with a general consensus that the gradual taper of benzodiazepines over a period of several months is the optimal approach. However, patients with benzodiazepine dependence are typically referred for inpatient detoxification treatment, which rapidly tapers patients off benzodiazepines. Protracted withdrawal symptoms frequently persist after discharge, predisposing patients to relapse. More effective pharmacotherapeutic strategies are needed for the treatment of benzodiazepine dependence in the outpatient setting.
Gabapentin has proven to be a safe and well-tolerated medication with a low abuse liability,
thereby making it ideal for use in the outpatient setting.
The proposed Exploratory Development research project is a double-blind randomized controlled
clinical trial comparing the efficacy of gabapentin to placebo for the outpatient treatment
of benzodiazepine dependence. The goal of this project is to study the effects of gabapentin
on the participants' benzodiazepine use in a facilitated taper-to-abstinence model, where
participants will be actively using benzodiazepines at study entry, gabapentin treatment will
be introduced, and participants will be counseled to gradually discontinue benzodiazepine use
over the study period while gabapentin treatment is maintained. A modified version of Medical
Management will be used to facilitate compliance with study medication and other study
procedures, and includes clinical instruction for gradually reducing benzodiazepine use 25%
per week. Benzodiazepines are not prescribed in the proposed study; participants continue to
obtain benzodiazepines from their own prescribed or nonprescribed sources.
;
Status | Clinical Trial | Phase | |
---|---|---|---|
Withdrawn |
NCT04533230 -
Prevention of Benzodiazepine Misuse in Primary Care
|
N/A | |
Completed |
NCT02127411 -
Effectiveness of Mindfulness Based Relapse Prevention for Chronic Users of Benzodiazepines
|
N/A | |
Terminated |
NCT03192514 -
Electronic Deprescribing Tool for the Prevention of PIP
|
N/A | |
Not yet recruiting |
NCT05765656 -
Effectiveness of a Joint General Practitioner-Pharmacist Intervention on Benzodiazepine Deprescribing in the Elderly
|
N/A | |
Not yet recruiting |
NCT05935553 -
Baclofen for Improving Benzodiazepine Titration in Benzodiazepine Dependence
|
Phase 2/Phase 3 | |
Completed |
NCT03937180 -
Blended Care for the Discontinuation of Benzodiazepine Use
|
N/A | |
Active, not recruiting |
NCT04572750 -
Promoting Benzodiazepine Cessation Through an Electronically-delivered Patient Self-management Intervention
|
N/A | |
Recruiting |
NCT02475538 -
Electroacupuncture for Tapering Off Long-term Benzodiazepine Use
|
N/A | |
Completed |
NCT00420771 -
Gabapentin Treatment of Benzodiazepine Abuse in Methadone Maintenance Patients
|
Phase 2 | |
Recruiting |
NCT06250842 -
Benzodiazepine Impact on Cognitive Function: fNIRs and PET/MRI Study
|
||
Completed |
NCT03971097 -
The Effect of Self-Forgiveness on Self-Stigma in Addiction.
|
N/A | |
Not yet recruiting |
NCT06359314 -
Anxiety Lowering and Deprescribing Through Emotion Regulation
|
N/A |